Status:
COMPLETED
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
18-99 years
Phase:
PHASE1
Brief Summary
This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment M...
Eligibility Criteria
Inclusion
- Pathologic diagnosis of any solid tumor
- Incurable cancer, with disease progression following at least 1 therapy with no further standard treatment available in the opinion of the investigator.
- At least 1 evaluable lesion per RECIST criteria
Exclusion
- Clinically unstable primary or metastatic CNS tumors
- Subjects with known diabetes
- QTc interval greater than 470 ms.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00940498
Start Date
January 1 2010
End Date
October 1 2012
Last Update
November 2 2018
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
3
Dana-Farber Cancer Insitute
Boston, Massachusetts, United States, 02215
4
Mayo Clinic
Rochester, Minnesota, United States, 55905